$SPRB News

B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

Spruce Biosciences Joins the Russell 3000® Index

Spruce Biosciences Joins Russell 3000 Index, Effective June 29

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS Symposium

HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate

Craig-Hallum Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $140

Spruce Biosciences shares are trading lower after the company announced the pricing of its $60 million offering of 1.15 million shares and pre-funded warrants at $50 per share.

Spruce Biosciences shares are trading lower after the company announced the pricing of its $60 million offering of 1.15 million shares and pre-funded warrants at $50 per share.

Why Is Spruce Biosciences Stock Sinking Tuesday?

Reported Earlier, Spruce Biosciences Prices Public Offering Of 1.15M Shares And Pre-Funded Warrants At $50.00 Per Share, Raising $60M Gross Proceeds

Spruce Biosciences shares are trading lower after the company announced a public offering.

Spruce Biosciences Commences Proposed Public Offering; Terms Not Disclosed